TuisREGN34 • BVMF
add
Regeneron Pharmaceuticals Inc BDR
Vorige sluiting
R$56,22
Dagwisseling
R$56,06 - R$56,06
Jaarwisseling
R$55,00 - R$111,62
Markkapitalisasie
65,88 mjd USD
Gemiddelde volume
987,00
In die nuus
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
| (USD) | Des. 2024info | J/J-verandering |
|---|---|---|
Inkomste | 3,79 mjd | 10,33% |
Bedryfskoste | 792,20 m | 7,46% |
Netto inkomste | 917,70 m | -20,86% |
Netto winsgrens | 24,22 | -28,28% |
Wins per aandeel | 12,07 | 1,77% |
EBITDA | 1,15 mjd | 2,69% |
Effektiewe belastingkoers | 4,22% | — |
Balansstaat
Totale bates
Totale aanspreeklikheid
| (USD) | Des. 2024info | J/J-verandering |
|---|---|---|
Kontant en korttermynbeleggings | 9,01 mjd | -16,90% |
Totale bates | 37,76 mjd | 14,15% |
Totale aanspreeklikheid | 8,41 mjd | 18,27% |
Totale ekwiteit | 29,35 mjd | — |
Uitstaande aandele | 107,02 m | — |
Prys om te bespreek | 0,21 | — |
Opbrengs op bates | 6,78% | — |
Opbrengs op kapitaal | 7,92% | — |
Kontantvloei
Netto kontantverandering
| (USD) | Des. 2024info | J/J-verandering |
|---|---|---|
Netto inkomste | 917,70 m | -20,86% |
Kontant van bedrywe | 1,26 mjd | 15,89% |
Kontant van beleggings | 350,60 m | 629,61% |
Kontant van finansiering | -1,14 mjd | -154,54% |
Netto kontantverandering | 477,20 m | -17,38% |
Beskikbare kontantvloei | 936,12 m | 70,83% |
Meer oor
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. The company was founded in 1988. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its present name; the company has since expanded operations into the study of both cytokine and tyrosine kinase receptors, which gave rise to their first product, which is a VEGF-trap. Wikipedia
Gestig
1988
Hoofkwartier
Webwerf
Werknemers
15 106
